Emcure Pharmaceuticals has slashed the price of its weight management drug, Poviztra (semaglutide injection), making it available across India starting at ₹3,999 for a monthly pack of four weekly doses.

The innovator Semaglutide is provided in a once-weekly injection pen, offering five distinct strengths: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and a 2.4 mg maintenance dose. Featuring a state-of-the-art design, this device ensures simple administration and precise, reliable dosing.

As the first Indian company to exclusively commercialise Novo Nordisk’s second semaglutide brand, Poviztra, Emcure Pharmaceuticals has announced a major price revision. This initiative aims to expand access to obesity treatment across all dosage strengths.